Repare in progress
Synthetic lethality play Repare emerges from stealth with $68M series A
With a $68 million series A co-led by Versant Ventures and MPM Capital, Repare Therapeutics Inc. emerged from 18 months of stealth today, making a splash in the growing pool of newcos targeting cancer via synthetic lethality. The company thinks its CRISPR screening platform will yield a deep, well-validated pipeline that could bring two lead compounds to the clinic in 2019.
Synthetic lethality occurs when deficiencies